Company news
Celularity Inc. news in 2026
Celularity Inc.'s news releases, calls and decks from 2026, newest first.
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
October 29, 2026
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
October 22, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
October 20, 2026
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
September 30, 2026
Celularity Announces Naveen Jain to Join Board of Directors
September 29, 2026
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
September 24, 2026
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
August 27, 2026
Celularity Provides Update Regarding Nasdaq Listing Compliance
August 25, 2026
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
June 3, 2026
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
June 3, 2026
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
May 1, 2026
Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
April 30, 2026
Celularity Announces Closing of Transaction with NexGel
April 21, 2026
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 17, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4: 30 P.M. ET to Provide Update on Celularity Transaction
April 15, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4: 30 P.M. ET to Provide Update on Celularity Transaction
April 8, 2026
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4: 30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
March 31, 2026
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
March 11, 2026
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
March 9, 2026
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
February 10, 2026